The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection
The invention includes compositions and methods for regulating p110 delta as an anti-influenza virus therapy. The invention includes inhibiting p110 delta, a component of p110 delta signaling pathway, or any combination thereof in a cell as an anti-influenza viral therapeutic approach for treating influenza virus infection. The invention includes a method of modulating p110 delta in a cell by contacting the cell with an effective amount of a composition comprising an inhibitor of p110 delta.
1 . A composition for inhibiting influenza virus infection, said composition comprising an inhibitor of phosphoinositide 3 kinase (PI3K) isoform p110 delta, wherein said inhibitor interferes with PI3K p110 delta activation and replication of said influenza virus.
2 . The composition of claim 1 , wherein said inhibitor interferes with influenza virus pathogenesis.
3 . The composition of claim 1 , wherein said inhibitor is selected from the group consisting of a small interfering RNA (siRNA), a microRNA, an antisense nucleic acid, a ribozyme, an expression vector encoding a transdominant negative mutant, an intracellular antibody, a peptide and a small molecule.
4 . The composition of claim 1 , further comprising a physiologically acceptable carrier.
5 . A method of inhibiting influenza virus replication in a cell, said method comprising contacting said cell with a composition comprising an inhibitor of PI3K p110 delta, wherein said contacting inhibits phosphoinositide 3 kinase (PI3K) isoform p110 delta in said cell, thereby inhibiting influenza virus replication in said cell.
6 . The method of claim 5 , wherein said inhibitor is selected from the group consisting of a small interfering RNA (siRNA), a microRNA, an antisense nucleic acid, a ribozyme, an expression vector encoding a transdominant negative mutant, an antibody, a peptide, and a small molecule.
7 . The method of claim 5 , wherein said composition further comprises a physiologically acceptable carrier.
8 . A method of inhibiting influenza virus pathogenesis in a cell, said method comprising contacting said cell with a composition comprising an inhibitor of PI3K p110 delta, wherein said contacting inhibits phosphoinositide 3 kinase (PI3K) isoform p110 delta in said cell, thereby inhibiting influenza virus pathogenesis in said cell.
9 . The method of claim 8 , wherein said inhibitor is selected from the group consisting of a small interfering RNA (siRNA), a microRNA, an antisense nucleic acid, a ribozyme, an expression vector encoding a transdominant negative mutant, an antibody, a peptide, and a small molecule.
10 . The method of claim 8 , wherein said composition further comprises a physiologically acceptable carrier.
11 . A method of treating or preventing influenza virus infection in a mammal, said method comprising administering to said mammal an effective amount of a composition comprising an inhibitor of phosphoinositide 3 kinase (PI3K) isoform p110 delta, wherein said administering of said composition to said mammal interferes with PI3K p110 delta activation and replication of influenza virus in said mammal, thereby treating or preventing said virus infection in said mammal.
12 . The method of claim 11 , wherein said inhibitor is selected from the group consisting of a small interfering RNA (siRNA), a microRNA, an antisense nucleic acid, a ribozyme, an expression vector encoding a transdominant negative mutant, an intracellular antibody, a peptide and a small molecule.
13 . The method of claim 11 , wherein said composition further comprising a physiologically acceptable carrier.
14 . The method of claim 11 , wherein said mammal is a human.